Imperial College London
Portrait Picture

DrJuliaMakinde

Faculty of Medicine, Department of Infectious Disease

Honorary Lecturer
 
 
 
//

Contact

 

j.makinde

 
 
//

Location

 

Chelsea and Westminster HospitalChelsea and Westminster Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Fernandez:2022:10.3389/fimmu.2022.1029029,
author = {Fernandez, N and Hayes, P and Makinde, J and Hare, J and King, D and Xu, R and Rehawi, O and Mezzell, AT and Kato, L and Mugaba, S and Serwanga, J and Chemweno, J and Nduati, E and Price, MA and Osier, F and Ochsenbauer, C and Yue, L and Hunter, E and Gilmour, J and IAVI, PCI},
doi = {10.3389/fimmu.2022.1029029},
journal = {Frontiers in Immunology},
pages = {1--15},
title = {Assessment of a diverse panel of transmitted/founder HIV-1 infectious molecular clones in a luciferase based CD8 T-cell mediated viral inhibition assay},
url = {http://dx.doi.org/10.3389/fimmu.2022.1029029},
volume = {13},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Introduction: Immunological protection against human immunodeficiency virus-1 (HIV-1) infection is likely to require both humoral and cell-mediated immune responses, the latter involving cytotoxic CD8 T-cells. Characterisation of CD8 T-cell mediated direct anti-viral activity would provide understanding of potential correlates of immune protection and identification of critical epitopes associated with HIV-1 control.Methods: The present report describes a functional viral inhibition assay (VIA) to assess CD8 T-cell-mediated inhibition of replication of a large and diverse panel of 45 HIV-1 infectious molecular clones (IMC) engineered with a Renilla reniformis luciferase reporter gene (LucR), referred to as IMC-LucR. HIV-1 IMC replication in CD4 T-cells and CD8 T-cell mediated inhibition was characterised in both ART naive subjects living with HIV-1 covering a broad human leukocyte antigen (HLA) distribution and compared with uninfected subjects.Results & discussion: CD4 and CD8 T-cell lines were established from subjects vaccinated with a candidate HIV-1 vaccine and provided standard positive controls for both assay quality control and facilitating training and technology transfer. The assay was successfully established across 3 clinical research centres in Kenya, Uganda and the United Kingdom and shown to be reproducible. This IMC-LucR VIA enables characterisation of functional CD8 T-cell responses providing a tool for rational T-cell immunogen design of HIV-1 vaccine candidates and evaluation of vaccine-induced T-cell responses in HIV-1 clinical trials.
AU  - Fernandez,N
AU  - Hayes,P
AU  - Makinde,J
AU  - Hare,J
AU  - King,D
AU  - Xu,R
AU  - Rehawi,O
AU  - Mezzell,AT
AU  - Kato,L
AU  - Mugaba,S
AU  - Serwanga,J
AU  - Chemweno,J
AU  - Nduati,E
AU  - Price,MA
AU  - Osier,F
AU  - Ochsenbauer,C
AU  - Yue,L
AU  - Hunter,E
AU  - Gilmour,J
AU  - IAVI,PCI
DO  - 10.3389/fimmu.2022.1029029
EP  - 15
PY  - 2022///
SN  - 1664-3224
SP  - 1
TI  - Assessment of a diverse panel of transmitted/founder HIV-1 infectious molecular clones in a luciferase based CD8 T-cell mediated viral inhibition assay
T2  - Frontiers in Immunology
UR  - http://dx.doi.org/10.3389/fimmu.2022.1029029
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000898370900001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
UR  - https://www.frontiersin.org/articles/10.3389/fimmu.2022.1029029/full
UR  - http://hdl.handle.net/10044/1/105602
VL  - 13
ER  -
Download